PMID- 27976513
OWN - NLM
STAT- MEDLINE
DCOM- 20180312
LR  - 20221207
IS  - 1753-0407 (Electronic)
IS  - 1753-0407 (Linking)
VI  - 9
IP  - 6
DP  - 2017 Jun
TI  - What next after basal insulin? Treatment intensification with lixisenatide in 
      Asian patients with type 2 diabetes mellitus.
PG  - 562-574
LID - 10.1111/1753-0407.12515 [doi]
AB  - There is increasing evidence that the pathophysiology of type 2 diabetes mellitus 
      (T2DM) in Asian patients differs from that in Western patients, with early phase 
      insulin deficiencies, increased postprandial glucose excursions, and increased 
      sensitivity to insulin. Asian patients may also experience higher rates of 
      gastrointestinal adverse events associated with glucagon-like peptide-1 receptor 
      agonists (GLP-1RAs), such as nausea and vomiting, compared with their Western 
      counterparts. These factors should be taken into consideration when selecting 
      therapy for basal insulin treatment intensification in Asian patients. However, 
      the majority of studies to establish various agents for treatment intensification 
      in T2DM have been conducted in predominantly Western populations, and the levels 
      of evidence available in Chinese or Asian patients are limited. This review 
      discusses the different mechanisms of action of short-acting, prandial, and 
      long-acting GLP-1RAs in addressing hyperglycemia, and describes the rationale and 
      available clinical data for basal insulin in combination with the short-acting 
      prandial GLP-1RA lixisenatide, with a focus on treatment of Asian patients with 
      T2DM.
CI  - (c) 2016 Ruijin Hospital, Shanghai Jiaotong University School of Medicine and John 
      Wiley & Sons Australia, Ltd.
FAU - Chan, Wing B
AU  - Chan WB
AD  - Endocrinology, Diabetes & Metabolism, Qualigenics Diabetes Centre, Hong Kong, SAR 
      China.
FAU - Luk, Andrea
AU  - Luk A
AD  - Department of Medicine and Therapeutics, Chinese University of Hong Kong, Prince 
      of Wales Hospital, Hong Kong, SAR China.
FAU - Chow, Wing S
AU  - Chow WS
AD  - Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong 
      Kong, SAR China.
FAU - Yeung, Vincent T F
AU  - Yeung VTF
AD  - Department of Medicine and Geriatrics, Our Lady of Maryknoll Hospital, Hong Kong, 
      SAR China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20170123
PL  - Australia
TA  - J Diabetes
JT  - Journal of diabetes
JID - 101504326
RN  - 0 (Blood Glucose)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
RN  - 0 (Peptides)
RN  - 74O62BB01U (lixisenatide)
SB  - IM
MH  - Asian People
MH  - Blood Glucose/metabolism
MH  - China
MH  - Diabetes Mellitus, Type 2/*blood/*drug therapy/ethnology
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Hypoglycemic Agents/therapeutic use
MH  - Insulin/*therapeutic use
MH  - Peptides/*therapeutic use
MH  - Postprandial Period
OTO - NOTNLM
OT  - 2型糖尿病
OT  - insulin
OT  - lixisenatide
OT  - type 2 diabetes mellitus
OT  - 利西那肽
OT  - 胰岛素
EDAT- 2016/12/16 06:00
MHDA- 2018/03/13 06:00
CRDT- 2016/12/16 06:00
PHST- 2016/06/24 00:00 [received]
PHST- 2016/11/25 00:00 [revised]
PHST- 2016/12/06 00:00 [accepted]
PHST- 2016/12/16 06:00 [pubmed]
PHST- 2018/03/13 06:00 [medline]
PHST- 2016/12/16 06:00 [entrez]
AID - 10.1111/1753-0407.12515 [doi]
PST - ppublish
SO  - J Diabetes. 2017 Jun;9(6):562-574. doi: 10.1111/1753-0407.12515. Epub 2017 Jan 
      23.